Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 5 years
- Director since
- 2023
5 years of board service in total across 2 boards, counting each seat separately. Longest: Denali Therapeutics Inc., 3 years.
Denali Therapeutics Inc.
Director
Rezolute Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Apr 16, 2026 | Ultragenyx Pharmaceutical Inc. | Grant or award | +28,895 | — | — |
| Mar 2, 2026 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −10,539 | $22.80 | $240,289 |
| Mar 1, 2026 | Ultragenyx Pharmaceutical Inc. | Grant or award | +11,643 | — | — |
| Nov 19, 2025 | Rezolute Inc. | Grant or award | +21,000 | — | — |
| Mar 3, 2025 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −15,103 | $42.10 | $635,836 |
| Mar 1, 2025 | Ultragenyx Pharmaceutical Inc. | Grant or award | +16,813 | — | — |
| Mar 1, 2025 | Ultragenyx Pharmaceutical Inc. | Grant or award | +18,443 | — | — |
| May 31, 2024 | Denali Therapeutics Inc. | Grant or award | +5,967 | — | — |
| Mar 1, 2024 | Ultragenyx Pharmaceutical Inc. | Grant or award | +19,400 | — | — |
| Mar 1, 2024 | Ultragenyx Pharmaceutical Inc. | Grant or award | +957 | — | — |
| Mar 1, 2024 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −4,768 | $53.76 | $256,328 |
| Sep 5, 2023 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −6,000 | $37.96 | $227,760 |
| Jun 19, 2023 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −305 | $48.20 | $14,701 |
| Jun 1, 2023 | Denali Therapeutics Inc. | Grant or award | +4,216 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.